Biohaven

Update in progress

BHVN (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Biohaven Ltd. is a biopharmaceutical company focused on therapies for immunology, neuroscience and oncology worldwide. Its Phase 3 programs include BHV-8000 for Parkinson’s disease and Opakalim for focal epilepsy. Phase 2 programs cover BHV-1300 (Graves’ disease, RA), BHV-1400 (IgA nephropathy), BHV-1600 (peripartum cardiomyopathy), BHV-2100 (pain), BHV-2000 (obesity), BHV-1510 (epithelial tumors) and BHV-1530 (urothelial cancer). Preclinical BHV-1310, 1320, 1450, 1420, 1440, 6500, 1490, 8100, 1955. Formerly Biohaven Research Ltd; renamed Sept 2022. Based in New Haven, CT.

Company score

Sentiment: -0.17; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.38; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive